Regemat 3D

Regemat 3D is a Spanish company that manufactures customizable 3D bioprinting systems and bioreactors for tissue engineering applications. Its flagship products include the BIO V1 and REG4LIFE 3D bioprinters, which allow users to combine different 3D printing techniques like extrusion, photocuring, and thermoplastic printing. These bioprinters have been used for applications such as skin, cartilage, and cornea tissue engineering, disease modeling, and drug testing.

Regemat 3D's bioprinting platforms are modular and can be configured with various interchangeable print heads (e.g., cooled/heated syringes, UV curing) to meet specific research needs. For instance, the bioprinters can operate at temperatures ranging from -20°C to 100°C for printing temperature-sensitive biomaterials. They also offer independent control of the print bed and syringe temperatures.

As of May 2022, Regemat 3D had sold its bioprinters to over 100 research institutions across 29 countries. The company launched its REG4LIFE bioprinter and a bioreactor for articular cartilage manufacturing in 2020 after a successful crowdfunding campaign. In November 2022, Regemat 3D plans to open another crowdfunding round to prepare for an initial public offering (IPO) targeted for late 2023 or early 2024.